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Retinal Cell Biology
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PURPOSE. To investigate, using in vivo and in vitro models, retinal ganglion cell (RGC)
neuroprotective and axon regenerative effects and underlying mechanisms of siRTP801, a
translatable small-interfering RNA (siRNA) targeting the mTOR negative regulator RTP801.
METHODS. Adult rats underwent optic nerve (ON) crush (ONC) followed by intravitreal
siRTP801 or control siRNA (siEGFP) every 8 days, with Brn3aþ RGC survival, GFAPþ reactive
gliosis, and GAP43þ regenerating axons analyzed immunohistochemically 24 days after injury.
Retinal cultures, prepared from uninjured animals or 5 days after ONC to activate retinal glia,
were treated with siRTP801/controls in the presence/absence of rapamycin and subsequently
assessed for RGC survival and neurite outgrowth, RTP801 expression, glial responses, and
mTOR activity. Conditioned medium was analyzed for neurotrophin titers by ELISA.
RESULTS. Intravitreal siRTP801 enabled 82% RGC survival compared to 45% with siEGFP 24
days after ONC, correlated with greater GAP43þ axon regeneration at 400 to 1200 lm beyond
the ONC site, and potentiated the reactive GFAPþ Mu¨ller glial response. In culture, siRTP801
had a direct RGC neuroprotective effect, but required GFAPþ activated glia to stimulate
neurite elongation. The siRTP801-induced neuroprotection was significantly reduced, but not
abolished, by rapamycin. The siRTP801 potentiated the production and release of
neurotrophins NGF, NT-3, and BDNF, and prevented downregulation of RGC mTOR activity.
CONCLUSIONS. The RTP801 knockdown promoted RGC survival and axon elongation after
ONC, without increasing de novo regenerative sprouting. The neuroprotection was
predominantly direct, with mTORC1-dependent and -independent components. Enhanced
neurite/axon elongation by siRTP801 required the presence of activated retinal glia and was
mediated by potentiated secretion of neurotrophic factors.
Keywords: neuroprotection, axon regeneration, RNA interference
Traumatic optic neuropathy, resulting from ocular or headinjuries that directly or indirectly damage the optic nerve
(ON), is associated with retinal ganglion cell (RGC) death and
ensuing visual loss.1 Although spontaneous visual improvement
occurs in a minority of patients, permanent visual impairment
is frequent and currently there are no clinically effective
treatments.2–4
The RGC death, which commences within 5 to 6 days after
ON injury with more than 90% RGC loss by 14 days,5 is
preventable by either downregulation of proapoptotic cas-
pases6–8 or upregulation of antiapoptotic mediators, such as
Bcl-29,10 and Bcl-XL.11 However, axon regeneration is not an
inevitable correlate of RGC survival, as independent factors
mediate both events.7,12 For example, protection against axon
growth cone collapse (mediated through the Ras homolog gene
A/rho-associated kinase [RhoA/ROCK] pathway12,13) does not
promote significant axonal regeneration in the absence of
neurotrophic factor (NTF) stimulation, which drives axon
growth by inducing axogenic protein synthesis and supporting
growth cone dynamics.12,14–16 The neurotrophin family
includes nerve growth factor (NGF), brain-derived NTF (BDNF),
neurotophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5), which
are produced by activated astrocytes and Mu¨ller glia after
injury, and act on tyrosine kinase (Trk) receptors to modulate
growth-promoting cellular signaling pathways.17–19 In addition,
other NTFs, such as ciliary neurotrophic factor (CNTF), glia-
cell-line–derived neurotrophic factor (GDNF), and basic fibro-
blast growth factor (FGF2), also promote RGC survival and
axon regeneration and, in combination with axogenic neuro-
trophins, act synergistically to stimulate RGC axon growth.17,20
Activated-glial–derived NTFs are essential for promoting RGC
survival and axon regeneration after ON injury,12,19,21–25 and
therefore modulation of the glial response after injury is likely
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to be beneficial for the development of an effective translatable
neuroprotective and axogenic treatment strategy.
A reduction in intrinsic axon growth potential during
development also contributes to the failure of axon regener-
ation in the mature central nervous system (CNS) after injury.26
Key intrinsic determinants of axogenesis include cyclic AMP
(cAMP), Kru¨ppel-like transcription factors (KLF), and the
serine-threonine kinase mammalian target of rapamycin
(mTOR).27–29 The contribution of mTOR to axogenic signaling
has been the focus of much recent research interest. Although
active during development, mTOR is downregulated in the
mature CNS, probably through the progressive upregulation of
phosphatase and tensin homolog (PTEN), a negative regulator
of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway.30
Deletion of PTEN promotes activation of mTOR signaling and
inactivation of GSK3b, enabling RGC survival and axon
regeneration after ON crush (ONC).29,31,32 Deletion of PTEN
similarly enhances the regenerative potential of spinal cortico-
spinal tract and peripheral sensory axons.33–35 The activity of
mTOR is further downregulated after ONC, as evidenced by
reduced expression of phosphorylated ribosomal S6 protein
(pS6), a widely used downstream indicator of mTOR activity.31
Deletion of PTEN prevents ONC-induced suppression of pS6
expression in up to 10% of surviving RGCs, correlated with
axon regeneration in 8% to 10% surviving RGCs, confirming
pS6 expression as a possible key marker of intrinsic axon
regenerative ability.29,31 However, limited axon regeneration is
still observed in the presence of the mTOR complex 1
(mTORC1) inhibitor rapamycin,31 suggesting that mTORC1-
independent factors may also contribute, such as via mTOR
complex 2 (mTORC2) or other pathways.
Hypoxia, energy deprivation, DNA damage, and reduced
nutrient availability all inhibit mTOR-mediated protein synthe-
sis,36 and the TSC1/2 complex is a key nodal point in the
negative regulation of mTOR function. In the canonical PI3K/
Akt-signaling cascade, the TSC1/2 complex is phosphorylated
and inhibited by Akt, thereby allowing accumulation of Rheb-
GTP and subsequent activation of mTOR.37 Cells deficient for
TSC1/2 fail to suppress mTOR activity in conditions of energy
deprivation.38,39 Hypoxia and cellular stress promote the rapid
induction of RTP801 (also known as DDIT4/Redd1), which
activates the TSC1/2 complex to downregulate mTOR activi-
ty.37,40 Moreover, AMP-activated kinase, which mediates mTOR
downregulation in response to impaired cellular energy
production via TSC1/2, activates RTP801 to reduce mTOR
activity.41 RTP801 is closely linked to regulation of neuronal
development and viability, is a negative regulator of neurogen-
esis during embryologic development, and RTP801 knock-
down accelerates cell cycle exit by neural progenitors and their
differentiation into neurons.42 Upregulation of RTP801 is
associated with the induction of neuronal apoptosis,43 and
suppression of RTP801 has demonstrated neuroprotective
effects in retinal neurons in vitro and in vivo.44,45 Therefore,
targeting the stress-induced factor RTP801 is a potentially
viable strategy to promote mTOR activity after injury, and
enhance CNS neuroprotection and axogenesis.
This study investigated the RGC neuroprotective and ON
axon regenerative effects and underlying mechanisms of
siRTP801, a therapeutically translatable small-interfering RNA
(siRNA) that effectively knocks down the mTOR negative
regulator RTP801 and is currently in clinical development for
nonneuroprotective indications.46–50 We show that siRTP801
supports RGC survival and elongation of regenerating axons, a
response that is accompanied by potentiated reactive gliosis
after ONC in vivo in the absence of nonspecific proinflamma-
tory activity. In retinal cultures, RGC neuroprotection is
directly induced by siRTP801 through both mTORC1-depen-
dent and independent pathways, whereas the neurite elonga-
tion effect of siRTP801 is indirect, requiring the presence of
activated glial fibrillary acidic protein (GFAPþ) retinal glia–
derived NTF. Moreover, siRNA-mediated knockdown of RTP801
prevents downregulation of pS6 expression in RGCs, although
the latter is not an absolute requirement for neurite growth.
Our results suggest that siRTP801 is RGC neuroprotective and
supports elongation of regenerating axons via direct and
indirect mechanisms and may have potential for the treatment
of traumatic optic neuropathy.
METHODS
Experimental Design
An initial series of in vivo studies was undertaken to evaluate
various combinations of siRNA targeting aspects of cellular
signaling, and siRTP801 was identified as a suitable candidate
for further study and used without combination in the results
presented here. Specific details of methodology and results
pertaining to siRTP801 in RGC survival, axon regeneration, and
glial activation in these initial studies are given in Supplemen-
tary Tables S1 through S3 to support the present data. The
siRTP801 target specificity and the lack of nonspecific
proinflammatory activity in the retina after intravitreal
injection were confirmed by RNA ligase–mediated rapid
amplification of cDNA ends (RLM-RACE) and monitoring
expression of interferon-inducible genes, respectively. In vivo
and in vitro experiments were designed to evaluate RGC
neuroprotection and axon regeneration after the siRTP801-
mediated activation of mTOR (Fig. 1). After ONC, siRTP801
was intravitreally injected in one eye and control siEGFP to the
fellow eye 0, 8, and 16 days later. Tissue was harvested at 24
days for immunohistochemistry and analysis of RGC survival,
axon regeneration, glial activation, RTP801 expression, and
mTORC1 activity (pS6 expression). A group of uninjured
animals was used as intact controls (Fig. 1A), as a benchmark
for determining the effects of siRTP801 compared with
inactive control siRNA against enhanced green fluorescent
protein (siEGFP) after ON injury.
Retinal culture studies were undertaken to evaluate the
cellular mechanisms underlying the effects seen in vivo (Fig.
1B). Dissociated mixed cell cultures were obtained from adult
rat retinae, either uninjured or at 5 days after ONC to activate
retinal glia. Cultured cells were transfected with either
siRTP801 or control siEGFP or culture medium alone, all in
the presence or absence of the mTORC1 inhibitor rapamycin
and incubated for 3 days. Cultures were immunostained for
analysis of RGC survival, neurite outgrowth, siRTP801-target
knockdown, reactive glial marker expression, and mTORC1
activity. Culture medium from siRTP801-transfected and
control (siEGFP and culture medium alone) wells, both from
uninjured animal retinal cultures and after glial activation, was
assayed for neurotrophin titers by ELISA. All reagents were
purchased from Sigma (Poole, UK) unless otherwise stated.
Small-Interfering RNA
All siRNA molecules used in this study were stabilized by
alternating 20O-methylation as previously described,51 and
were chemically synthesized at BioSpring (Frankfurt, Ger-
many). The siRTP801 had sequence 50-GUGCCAACCUGAUG
CAGCU-30 (sense strand); siRNA against EGFP was as previ-
ously described.52 Previous in vivo studies using a similar
siRNA approach demonstrated detectable siRNA levels in the
retina up to 28 days after intravitreal injection, with half-life of
approximately 7 days.6
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In Vivo Experiments
Animals and Surgical Procedures. All studies using
experimental animals were conducted in adherence to the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research. Adult male Wistar rats (Charles River, Kent,
UK), weighing 200 to 250 g at the commencement of
experiments, were housed at 218C/55% humidity in a 12-hour
light and dark cycle with ad libitum access to food and water.
All surgeries performed at University of Birmingham and
Neuregenix Ltd. were carried out under the UK Home Office
regulations for the care and use of experimental animals and
the UK Animals (Scientific Procedures) Act 1986, and
approved by the University of Birmingham Ethical Review
Committee. Inhalational anesthesia was induced with 5%
isoflurane with 1.5 L/min O2 (National Veterinary Supplies,
Stoke, UK) and maintained at 3% throughout surgery. After
surgery, lubricating Carbomer Gel 0.2% eye lubricant (Blumont
Healthcare, Grantham, UK) was applied, and animals recov-
ered from surgery in heated cages under supervision until the
emergence of normal behavior, when they were returned to
home cages. All animal procedures performed at the facilities
of Quark Pharmaceuticals, Inc., were reviewed and approved
by the Hebrew University Animal Research Committee in
Israel.
Optic Nerve Crush. After analgesia with subcutaneous
injection of buprenorphine (0.1 mL/100 g; National Veterinary
Supplies), animals were anesthetized, secured in a head-
holding frame, and underwent bilateral ONC as described
previously.53,54 Briefly, after a midline cutaneous incision, the
ON was exposed through a superior orbital approach and
crushed with forceps 2 mm from the lamina cribrosa, within
the dural sheath to sever all RGC axons while preserving
retinal vascular supply.
Intravitreal Injections and Treatment Schedule. Di-
rectly after ONC, intravitreal injections were performed using
glass micropipettes inserted immediately posterior to the
limbus, without damaging the lens. Animals were bilaterally
injected with of 20 lg siRNA, dissolved in 10 lL sterile PBS,
with intravitreal delivery of siRTP801 to one eye and control
siRNA (siEGFP) to the contralateral eye (n¼ 5 animals). Repeat
siRNA injections were delivered 8 and 16 days after ONC, and
tissue harvested at 24 days after ONC for processing and
analysis. An additional group of uninjured animals was used as
intact controls (n¼ 5 eyes) (Fig. 1A).
Tissue Preparation. At 24 days after ONC, animals were
killed by overdose of CO2 and perfused transcardially with PBS
followed by 4% paraformaldehyde (PFA; TAAB, Reading, UK).
Eyes and ONs were dissected and postfixed in 4% PFA for 2
hours at 48C. Tissue was cryoprotected sequentially in 10%,
20%, and 30% sucrose solutions in PBS for 24 hours at 48C,
embedded in optimal cutting temperature embedding medium
(Thermo Shandon, Runcorn, UK), frozen rapidly on dry ice,
and stored at 808C. Radial sections of eyes and longitudinal
ON sections were cut at 15 lm on a cryostat (Bright,
Huntingdon, UK), mounted on Superfrost Plus microscope
slides (Fisher Scientific, Pittsburgh, PA, USA), and stored at
208C until analysis. Sections of ON with a clearly demarcated
ONC site, and radial ocular sections taken through the ON
head were selected for analysis.
Immunohistochemistry. Eye and ON sections were
washed in rinsing buffer (0.1% Triton X-100 in PBS) for 3 3 5
minutes. Excess rinsing buffer was aspirated and a hydropho-
bic pen used to draw around each section. A 10% normal goat/
donkey serum (Vector Laboratories, Peterborough, UK) and 3%
BSA blocking solution was applied to each section to eliminate
nonspecific protein binding, and incubated in a humidified
chamber for 1 hour at room temperature. Blocking buffer was
removed and sections were then incubated with primary
antibodies (100 lL/section, Supplementary Table S4) in
antibody diluting buffer (ADB; 3% BSA in PBS) in a humidified
chamber overnight at 48C. Additional sections were prepared
as described, but in the absence of primary antibody to act as
negative controls (not shown). The following day, sections
were washed in rinsing buffer (335 minutes) and incubated in
a humidified chamber for 1 hour in the dark at room
temperature with appropriate secondary antibodies (100 lL/
section; Supplementary Table S4). Slides were then washed in
rinsing buffer (3 3 5 minutes) and coverslip mounted using
Vectashield with 40,6-diamidino-2-phenylindole (DAPI; Vector
Laboratories) and stored at 48C before microscopic analysis as
detailed below.
Assessment of RGC Survival and Axon Regeneration.
All sections were viewed under an upright Axioplan-2
fluorescence microscope and3200 magnification photomicro-
graph images captured with Axiovision software (both Carl
Zeiss Ltd., Hertfordshire, UK). Survival of RGCs was analyzed as
previously described.55 Briefly, RGCs were identified and
counted in a standard 250-lm linear strip of the ganglion cell
layer (GCL) in radial sections on either side of the ON head
(four radial sections/retina, n¼ 5 eyes/treatment group), using
FIGURE 1. Experimental design for in vivo and in vitro experiments.
(A) Timeline of in vivo study protocol, and treatment groups with
measured endpoints (IHC, immunohistochemistry). (B) Timeline of in
vitro studies, detailing retinal cultures obtained from uninjured adult
rats and 5 days after ONC to activate retinal glia, with measured
endpoints (ICC, immunocytochemistry). Treatment conditions includ-
ed siRTP801, siEGFP, and sNBA culture medium alone both in standard
and glial-activated cultures. Specific wells were also treated with the
mTORC1 inhibitor rapamycin.
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the RGC phenotypic antibody marker Brn3a,56 and results
were expressed as the mean number of RGCs per 250-lm GCL.
Survival analysis of RGCs in the initial in vivo studies used bIII-
tubulin as the RGC phenotypic marker (Supplementary Table
S1), which was superseded with the more specific Brn3a for
the studies reported here. Estimation of RGC numbers using
Brn3a immunostained retinal sections detects quantitatively
similar RGC loss compared with Brn3a-stained retinal whole-
mounts or FluoroGold (FG) back-labeled retinal whole-mounts,
while avoiding the additional surgery required for FG studies.
Retinal analysis is therefore simplified compared with whole-
mount preparations and enables both RGC survival and axon
regeneration analyses from the same animals, thereby reducing
animal usage and associated costs.56 Quantification of axon
regeneration in longitudinal ON sections was undertaken using
a method described previously.24 Briefly, composite images
were constructed from individual 3200 magnification ON
sections in Photoshop CS3 (Adobe Systems, Inc., San Jose, CA,
USA). The ONC site was identified by lamininþ staining and the
number of GAP43þ regenerating axons extending 100, 200,
400, 800, and 1200 lm from the center of the ONC site
counted (three sections/ON, n ¼ 5 eyes/group). We used
GAP43 to label regenerating axons because this is the gold
standard method of quantifying RGC axon regeneration in the
distal segment of the rat ON.57 In addition, a recent study from
our laboratory reported that the number of GAP43þ regener-
ating axons in the distal ON segment correlated with the
number of axons detected by the anterograde tracer Rhoda-
mine B.23 The cross-sectional width of the ON was measured at
the point at which axon counts were taken, and used to
calculate the number of axons/mm ON width. This value was
used to derive Rad, the total number of axons extending
distance d in an ON with radius r using the following formula:
Rad ¼ pr2xðaverage number of axons=mmwidthÞ=
ðsection thickness 0:015mmÞ
Assessment of Glial Activation. Astrocytes in the GCL/
nerve fiber layer (NFL) and Mu¨ller glial processes and somata
were detected using GFAP and S100b immunohistochemistry.
Mu¨ller glial processes and somata were quantified using a
method described previously.24 Radial retinal sections through
the ON head were immunostained for GFAP, an activated
astrocyte/Mu¨ller cell antibody marker. The number of GFAPþ
Mu¨ller cell processes intersecting a 250-lm horizontal linear
sampling line passing through the inner plexiform layer (IPL)
was counted at the midpoint between the GCL and inner
nuclear layer (INL) (four sections/retina, n ¼ 5 eyes/group).
Retinal sections were also immunostained for the S100b
protein, expressed by both activated and quiescent astro-
cytes/Mu¨ller glia.58 The number of S100bþ Mu¨ller glia somata
in the INL was also quantified along a 250-lm sample line (four
sections/retina, n¼ 5 eyes/group).
Assessment of RTP801 Expression and mTORC1
Activity. The RTP801 protein was detected in retinal sections
by immunohistochemistry. The RTP801þ RGCs were identified
by coimmunostaining with the RGC phenotypic marker Brn3a,
and reported as a percentage (6SEM) of the total RGC count in
the GCL sample. The RTP801þ/Brn3a nonneuronal cells of the
GCL were counted in the same 250-lm GCL linear sample as
described. Activity of mTORC1 was evaluated by immunohis-
tochemical detection of pS6 in retinal sections, and pS6þ RGC
reported as a percentage (6SEM) of the total RGC count in the
GCL sample.
Confirmation of RTP801-Specific RNA Interference
Following Intravitreal Administration of siRTP801. Spec-
ificity of siRTP801 was confirmed by detection of siRTP801-
specific RTP801 mRNA cleavage by RLM-RACE in the rat retina
in vivo. Adult male 180- to 220-g Sprague-Dawley rats (n ¼ 4/
treatment group) were given a 20-lg intravitreal injection of
either siRTP801 or siEGFP in 10 lL PBS per eye. Four hours
later, retinae were harvested and extracted RNA (EZ-RNA
extraction kit; Biological Industries, Beth HaEmek, Israel) was
analyzed using RLM-RACE to detect siRTP801-produced mRNA
cleavage product using GeneRacer Kit (Invitrogen, Carlsbad,
CA, USA), according to the manufacturer’s instructions. The
RNA samples extracted from cultured PC12 cells transfected
with siRTP801 were used as a positive control. The RACE
products were separated on 2% agarose gel, blotted, and
hybridized to the RACE product-specific oligonucleotide probe
(5 0-GGAGTAGAAATGATGCAGCT-3 0) labeled with c-33P-ATP.
After hybridization, the membrane was washed and exposed
to a KODAK BioMax film (Kodak, Rochester, NY, USA). The
following primers were used for the amplification of the
RTP801-RLM-RACE-product: 50-GGCTGTAACCAGGGACCAAG-
3 0 (RTP801-specific RT primer); 5 0-ATGCCAGGCGCAG
GAGTTCCTT-3 0 (RTP801-specific reverse PCR primer); 50-
AGGAGTTCCTTGCCCACCT-3 0 (RTP801-specific nested re-
verse PCR primer); 50-CGACTGGAGCACGAGGACACTGCAT-30
(adapter-specific forward PCR primer); and 50-GGACACTG
CATGGACTGAAGGAGTA-30 (adapter-specific nested forward
PCR primer).
Confirmation of the Lack of Nonspecific Proinflam-
matory Effects of Intravitreal siRTP801 Administration.
Sprague-Dawley rats (n ¼ 6/treatment group) were injected
intravitreally with either 20 mg per eye of poly(I:C) (200–1000
bp; Invivogen, Toulouse, France) in 10 mL PBS or 35 mg
siRTP801 in 10 mL PBS (19 bp; ~30-fold molar excess
compared with poly [I:C]). Control animals were injected with
10 mL PBS (the vehicle). Four or 24 hours after injection, eyes
were enucleated and retina/choroid complexes isolated for
RNA extraction (EZ-RNA extraction kit; Biological Industries)
and assessment of expression of IFN-responsive genes using
quantitative real-time RT-PCR (qPCR). The following amplifica-
tion primers were used (official gene symbols are shown in
parentheses): rat cyclophilin A (PPIA): forward: 5 0-
CGACTGTGGACAGCTCTAAT-3 0; reverse: 5 0-CCTGAGCTACA
GAAGGAATG-30; rat beta-actin (ACTB): forward: 50-AGAGC
TATGAGCTGCCTGAC-3 0; reverse: 5 0-AATTGAATGTAGTTT
CATGGATG-30; rat interferon-induced protein with tetratrico-
peptide repeats 1 (IFIT1): forward: 5 0-GCCTACGTGAGA
CACCTGAA-3 0; reverse: 5 0-AGGTCACCAGGCTTCTCTTG-3 0;
rat 20-50 oligoadenylate synthetase 1B (OAS1B): forward: 50-
TGATGTGCTTCCAGCCTATG-3 0; reverse: 5 0-TGCGCTCACT
GATGAGATTG-30.
In Vitro Experiments
Adult Rat Retinal Cultures. Animals were killed by CO2
overdose, and retinae dissociated into single cells using a
papain dissociation kit in accordance with the manufacturer’s
protocols (Worthington Biochemicals, Lakewood, NJ, USA), as
described previously.19,54 Retinal cells were plated at a density
of 125,000 cells per well into 8-well chamber slides (BD
Biosciences, Erembodegem, Belgium) precoated with poly-D-
lysine and laminin, in 300 lL/well Neurobasal A with B27
supplement and gentamicin (sNBA; all from Invitrogen, Paisley,
UK). To assess the effect of siRTP801 on RGC survival and
neurite outgrowth in the presence of activated retinal glia,
additional cultures were prepared from animals 5 days after
ONC (as described above).25 Cultures were incubated at 378C
and 5% CO2 overnight and subsequently transfected with
siRNA in the presence or absence of inhibitors.
Transfection of Retinal Cultures With siRNA and
Treatment With Rapamycin. Mixed retinal cell cultures
were transfected with siRNA using Lipofectamine 2000
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transfection reagent (Invitrogen) in accordance with the
manufacturer’s guidelines, as previously reported.59 In brief,
siRNA and transfection reagent were each diluted in sNBA
culture medium (without antibiotics) and incubated for 5
minutes at room temperature. The two solutions were
combined, gently mixed, and incubated for a further 25
minutes at room temperature to form siRNA-reagent complex-
es. Complexes were diluted to the desired concentrations in
medium, added to the cells, and transfected for 5 hours before
addition of sNBA to a final volume of 500 lL per well, and
incubated at 378C and 5% CO2 for 3 days. Culture medium
alone and Lipofectamine reagent without siRNA were used as
controls. A dose-response assay was undertaken initially, with
both siRTP801 and siEGFP tested at 10-nM, 20-nM, and 50-nM
concentrations, confirming that a concentration of 20 nM was
optimal for RGC neuroprotection (see Results) and used for
further experiments. Specific wells were also treated with
rapamycin (10 nM), added at the end of the siRNA transfection
period. In vitro experiments composed of two to three wells
per treatment condition, repeated with retinae from at least
three independent animals.
Immunocytochemistry. After incubation for 3 days, cell
culture medium was removed from wells and cells were fixed
in 4% PFA in PBS for 10 minutes before immunostaining. In
each well, cells were washed three times in rinsing buffer
(0.1% Triton X-100 in PBS), and nonspecific protein binding
blocked with 150 lL blocking buffer (10% normal goat/donkey
serum and 3% BSA in PBS) for 1 hour at room temperature.
Primary antibodies (150 lL/well in ADB; Supplementary Table
S4) were added to wells and cells incubated for 1 hour at room
temperature. Cells were then washed again (33 5 minutes) in
rinsing buffer and incubated with secondary antibodies (150
lL/well in ADB; Supplementary Table S4) for 1 hour at room
temperature in the dark. After further washes, chamber well
walls were removed from slides that were then coverslip
mounted with Vectashield containing DAPI (Vector Laborato-
ries) and viewed under fluorescence microscopy (Carl Zeiss
Ltd.).
Assessment of RGC Survival and Neurite Outgrowth.
Surviving RGCs were identified by bIII-tubulin immunostaining
(Supplementary Fig. S1). Each well was divided into a grid of 9
squares, and 4 photomicrographs (3200 magnification) were
captured within each square, giving a total of 36 images per
well. Counts of RGCs were undertaken from these images and
cell numbers per well determined from these samples. The bIII-
tubulinþRGC extending neurite(s) over a length greater than the
diameter of somata were identified (Supplementary Fig. S1). The
longest neurite per RGC was measured using Image Pro 6.2
(Media Cybernetics, Bethesda, MD, USA). The RTP801þ/bIII-
tubulinþ RGCs were expressed as a percentage of the total bIII-
tubulinþRGC population. The GFAPþ/S100bþglia were identified
immunocytochemically (Supplementary Fig. S1; Supplementary
Table S4) and quantified as described for RGCs.
Neurotrophic Factor ELISA. To evaluate NTF production
after siRNA treatment of cultured retinal cells, conditioned
medium was removed from wells for ELISA after 3 days of
incubation, immediately before fixing cells for immunocyto-
chemistry. Enzyme-linked immunosorbent assays for NGF,
neurotrophin-3 (NT3; both R&D Systems, Abingdon, UK), and
brain-derived neurotrophic factor (BDNF; Promega, Southamp-
ton, UK) were undertaken according to the manufacturers’
instructions. Briefly, test samples of conditioned medium were
run at graded concentrations (n ¼ 3 independent samples/
condition) and neurotrophin titers extrapolated from a standard
curve generated from the standard samples provided.
Statistics. Statistical tests were undertaken with SPSS 19.0
(IBM SPSS, Inc., Chicago, IL, USA) and data presented as means
6 SEM. All experimental results were derived from a minimum
of three independent replicates. For analysis of axon regener-
ation after ONC in vivo, the Student’s t-test was used to
compare treatment (siRTP801) with control (siEGFP) condi-
tions. All other comparisons between groups were undertaken
with ANOVA, followed by Dunnett or Tukey post hoc tests.
Statistical significance was considered at P less than 0.05.
RESULTS
In Vivo Experiments
Characterization of Specific and Nonspecific Activity
of siRTP801 in the Retina Following Intravitreal Injec-
tion. Detection of siRTP801-specific RTP801 mRNA cleavage
by RLM-RACE in the retina after intravitreal siRTP801 delivery
confirmed the specific activity of this siRNA in vivo (Fig. 2A).
The lack of induction of retinal expression of interferon-
responsive genes after intravitreal administration of siRTP801
confirmed the lack of proinflammatory (mediated by Toll-like
receptor [TLR] activation)60,61 effects of this compound
(Supplementary Fig. S2). There was a low level of RTP801
immunoreactivity in the GCL of retinal sections from intact
FIGURE 2. Confirmation of siRNA specificity and RTP801 expression/
knockdown in vivo. (A) Detection of siRTP801-specific RTP801 mRNA
cleavage by RLM-RACE in the retina in vivo. (B) Retinal sections
immunostained for Brn3a (green) and RTP801 (red) in the GCL of
intact retinae and 24 days after ONC þ siEGFP and ONC þ siRTP801
(scale bar: 100 lm). Note the presence of RTP801þ RGC (arrows) and
also RTP801 expression in nonneuronal cells (arrowheads). (C)
Quantification of RTP801þ RGC in a 250-lm GCL linear region of the
animals described in (B) (n¼ 5 retinae/group; ***P < 0.001), indicating
injury-induced RTP801 upregulation in RGC and target knockdown by
siRTP801. (D) Quantification of RTP801 activity in Brn3anonneuronal
cells of the GCL for the groups described in (B) (**P < 0.01, ***P <
0.001), indicating injury-induced RTP801 upregulation and target
knockdown by siRTP801.
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uninjured animals (Fig. 2B). Increased RTP801 protein was
detected in GCL cells of retinal sections 24 days after ONC and
intravitreal siEGFP, which was attenuated in sections from
ONC þ siRTP801 animals. Quantitatively, RTP801 positivity
was detected in 10.6% 6 1.1% Brn3aþ RGC in intact controls,
and significantly increased to 47.3% 6 3.1% (P < 0.001) of
remaining RGCs after ONCþ siEGFP. Treatment with siRTP801
significantly reduced the proportion of RTP801þ RGC com-
pared with siEGFP-injected eyes (21.9% 6 1.6%, P < 0.001)
(Fig. 2C). In addition to RGCs, RTP801 localized to Brn3a cells
of the GCL of intact animals, probably astrocytes/amacrine
cells (0.7 6 0.3 cells/250 lm GCL), with increased RTP801
detection in these cells after ONCþ siEGFP (3.5 6 0.4 cells, P
< 0.001), which was reduced after siRTP801 treatment (1.5 6
0.3 cells, P ¼ 0.001) (Fig. 2D). Together, these findings
indicated a low level constitutive RTP801 activity in the retina
of uninjured animals, increased RTP801 levels after ONC injury
in RGC and non-RGC cells, and attenuation of RTP801
immunoreactivity after siRTP801 treatment.
siRTP801 Promoted RGC Survival Up to 24 Days After
ONC. Compared with uninjured intact control animals (20.4 6
0.6 RGCs/250 lm GCL), there was a significant reduction (P <
0.001) in Brn3aþ RGC survival at 24 days after ONC and
intravitreal control siEGFP (9.2 6 0.6 RGCs) (Figs. 3A, 3B) or
PBS (not shown; see Supplementary Table S1). Intravitreal
treatment with siRTP801 promoted a significant increase (P <
0.001) in Brn3aþ RGC survival (16.9 6 0.6 RGC) compared with
animals receiving siEGFP at 24 days after ONC (Figs. 3A, 3B).
Treatment with siRTP801 allowed survival of 82% RGCs at 24
days after ONC, whereas RGC survival after siEGFP was 45%
compared with intact eyes. These results suggested that targeted
siRNA-mediated knockdown of RTP801 was RGC neuroprotec-
tive after ONC. The results of two supporting initial in vivo
experiments are summarized in Supplementary Table S1.
siRTP801 Promoted Longer Growth of Regenerating
Axons Up to 1200 lm Beyond the Injury Site Without
Affecting Initiation of Axon Growth After ONC. After
ONC, the number of GAP43þ regenerating RGC axons was
significantly greater at 400 lm (P < 0.05), 800 lm (P < 0.05),
and 1200 lm (P < 0.01) distal to the crush site after treatment
with siRTP801 (87.1 6 21.1, 68.9 6 11.2, 55.8 6 11.5 axons/
nerve, respectively) compared with siEGFP (44.9 6 23.0, 28.6
6 15.8, 15.4 6 9.9 axons/nerve, respectively) (Figs. 3C, 3D).
There was no significant difference in the number of GAP43þ
RGC axons in the ON at 100 lm and 200 lm distal to the
center of the ON crush site between siRTP801- and siEGFP-
injected animals. These results showed that siRTP801 and
control siEGFP treatments led to sprouting of similar numbers
of axons about the injury site, but siRTP801 treatment
sustained significantly longer growth of regenerating axons
after ONC. The results of two supporting initial in vivo
experiments are summarized in Supplementary Table S2.
siRTP801 Potentiated GFAPþ Glial Activation Without
Cellular Proliferation After ONC In Vivo. In the retina,
there was subdued GFAPþ (a marker of activated glia62)
astrocyte immunoreactivity in the NFL and GFAPþ Mu¨ller glial
processes were absent from the IPL in intact animals (Fig. 4A).
After ONC, GFAPþ immunoreactivity increased in the NFL, and
GFAPþ Mu¨ller glial processes traversed the IPL (Fig. 4A). The
number of GFAPþ Mu¨ller glial processes in the IPL was
significantly (P < 0.001) increased at 24 days after ONC in
retinae treated with siRTP801 (14.9 6 0.7/250 lm) compared
with siEGFP (10.2 6 0.5) after the same injury (Figs. 4A, 4B).
The number of S100bþ Mu¨ller glia somata (a marker of Mu¨ller
glia cells58,62,63) in the INL was unchanged after ONC in siEGFP
controls (16.6 6 0.4/250 lm) and siRTP801-treated retinae
(17.3 6 0.4) compared with intact retinae (16.7 6 0.5) (Figs.
4C, 4D). These data suggested that siRTP801 enhanced
activation of GFAPþ glia after ONC, without significantly
increasing Mu¨ller glial proliferation. The results of a previous
supporting independent evaluation of GFAPþ Mu¨ller glial
activation are summarized in Supplementary Table S3.
Injury-Induced Reduction in RGC mTORC1 Activity
Was Prevented by siRTP801. Immunohistochemical detec-
tion of pS6 was observed in the GCL of intact animals, although
was limited to a minority of Brn3aþ RGCs (15.4% 6 1.7% RGC,
Fig. 5). After ONCþ siEGFP, there was a significant reduction in
pS6 activity, localizing to only 5.9% 6 0.5% surviving RGCs (P
< 0.01) at 24 days after ONC. Treatment with siRTP801 was
associated with pS6 expression in 13.7% 6 1.4% RGCs at the
same time point after ONC, not significantly different from the
intact controls. Thus, the expression of pS6, a marker of
mTORC1 activity, was reduced by ONC injury and maintained
at preinjury levels by siRTP801 treatment.
In Vitro Experiments
Expression of RTP801 Was Knocked Down Both in
RGCs and Glia by siRTP801. The proportion of bIII-tubulinþ
RGC expressing RTP801 in vitro was significantly reduced (P <
0.001) from 88.3%6 5.9% and 79.0%6 5.5% in sNBA and siEGFP
control wells, respectively, to 26.3%6 8.8% after treatment with
FIGURE 3. Retinal ganglion cell survival and axon regeneration after
targeted knockdown of RTP801. (A) The Brn3aþ immunostained RGCs
in the GCL in intact retinae and 24 days after ONCþ siEGFP and ONCþ
siRTP801 treatments. Scale bar: 100 lm. (B) Quantification of Brn3aþ
RGC in a 250-lm linear region of the GCL in animals described in (A)
(n ¼ 5 retinae/group; **P < 0.01, ***P < 0.001). (C) Longitudinal ON
sections immunostained to demonstrate GAP43þ axons (arrows) after
ONCþ siEGFP– and ONCþ siRTP801–treated rats. Scale bar: 200 lm.
The asterisk demarcates ONC sites and the boxed area in the lower
panel represents a magnified area. Note that the increased number of
axons in the proximal ON segment (lower panel) correlates with
enhanced RGC survival. (D) Quantification of GAP43þ axons at 100,
200, 400, 800, and 1200 lm beyond the ONC site after ONC þ
siRTP801 (blue bars) and ONC þ siEGFP (red bars) (n ¼ 5 nerves/
group; *P < 0.05, **P < 0.01).
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siRTP801, indicating knockdown of RTP801 expression in RGCs
(Figs. 6A, 6C). In addition to RGCs, RTP801 expression was also
observed in a population of nonneuronal bIII-tubulin cells. The
observed number of RTP801þ/bIII-tubulincells was significantly
reduced (P< 0.001) after siRTP801 treatment (85.66 15.3 cells/
well) compared with sNBA (312.3 6 21.8) and siEGFP (420.3 6
17.9) controls, demonstrating target knockdown in cells other
than RGCs (Figs. 6B, 6C).
The siRTP801 Was RGC Neuroprotective, but Neither
Initiated Neurite Growth nor Increased Neurite Length
in the Absence of Activated Retinal Glia. In primary retinal
cultures established from intact rat eyes, 3-day siRTP801
treatment at concentrations of 10 nM, 20 nM, and 50 nM
significantly increased the survival of bIII-tubulinþ RGCs from
327.7 6 15.6 RGCs/well in untreated sNBA controls to 528.7
6 23.9, 620.7 6 15.6, and 533.3 6 23.3 RGCs, respectively
(P < 0.001, at each test concentration) (Figs. 6C, 6D). There
was no significant difference in RGC survival after incubation
of retinal cultures with the siRNA transfection agent Lipofect-
amine alone (294.3 6 13.9 RGC), or with siEGFP controls at
concentrations of 10 nM (264.3 6 13.9 RGCs), 20 nM (259.3
6 23.6 RGCs), and 50 nM (266.7 6 22.6 RGCs) (Fig. 6D).
Treatment of retinal cultures with siRTP801 at concentrations
of 10 nM, 20 nM, and 50 nM neither increased the proportion
of RGC-extending neurites, nor the length of RGC neurites
compared with controls (Figs. 6C, 6E, 6F).
There were no GFAPþ activated glia present after incubation
of retinal cell cultures prepared from intact eyes in the
presence of sNBA culture medium alone, siEGFP, or siRTP801
(Fig. 7A), demonstrating an absence of activated astrocytes per
Mu¨ller glia in this primary cell culture model. However, S100bþ
Mu¨ller glia were present in cultures prepared from intact eyes
and there was no significant difference in S100bþ glial number
among sNBA-, siEGFP-, and siRTP801-treated cultures (Figs. 7B,
7C). Of the observed S100b glia, 87.7% 6 5.2% and 84.3% 6
3.7% were also RTP801þ after sNBA and siEGFP treatments,
respectively (Figs. 7B, 7D), and treatment with siRTP801
significantly reduced the proportion of S100bþ/RTP801þglia to
36.7% 6 11.8% (P < 0.01 versus sNBA control, P < 0.05 versus
siEGFP control), indicating target knockdown in astrocytes and
Mu¨ller glia (Figs. 7B, 7D).
Treatment of retinal cultures with siRTP801 in vitro
therefore enhanced RGC survival in the absence of activated
retinal glia, but had no significant effect on either the initiation
of neurite outgrowth or the length of neurites. The data also
confirmed that treatment with siRNA was nontoxic in several
retinal cell populations, and did not lead to nonspecific glia
activation, as expected from the in vivo data demonstrating the
lack of TLR activation with subsequent induction of interferon
response (Supplementary Fig. S2).
The siRTP801 Reduced RTP801 Expression in Activat-
ed Retinal Glia but Did Not Promote Glial Proliferation.
Although absent from primary retinal cultures prepared from
intact animals, GFAPþ retinal glia were observed in cultures
prepared from retinae harvested at 5 days after astrocyte/
FIGURE 4. Retinal astrocyte/Mu¨ller glial response 24 days after ONC.
(A) Immunostained retinal sections showing GFAPþ glia in retinal
sections of intact uninjured retinae and in sections after ONCþ siEGFP
and ONCþ siRTP801. Scale bar: 100 lm. (B) Quantification of GFAPþ
Mu¨ller glia processes in a 250-lm linear region of the IPL in groups
described in (A) (n ¼ 5 retinae/group; ***P < 0.001). (C) Immuno-
stained retinal sections showing S100bþ Mu¨ller glia for the same
conditions as described in (A) (arrows indicate Mu¨ller glial somata;
scale bar: 100 lm). (D) Quantification of S100bþ Mu¨ller glia somata in
a 250-lm linear sample of the INL (n¼ 5 retinae/group).
FIGURE 5. Maintenance of RGC mTORC1 activity (pS6 expression)
after ONC in vivo. (A) Radial sections of the retina showing GCL
immunostained for pS6 in uninjured intact animals (left), and after
ONC þ siEGFP (middle) and ONC þ siRTP801 (right). Scale bar: 100
lm. (B) Higher magnification sections of GCL from groups described in
(A), immunostained for Brn3a (green) and pS6 (red), demonstrating
pS6þ RGC (arrows). Scale bar: 100 lm. (C) Quantification of pS6
expression in Brn3aþ RGC in retinal sections from groups described in
(A), demonstrating low-level constitutive mTORC1 activity, injury-
induced pS6 downregulation, and maintenance of RGC pS6 expression
after siRTP801 treatment (n ¼ 5 retinae/group; **P < 0.01).
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Mu¨ller glial activation by ONC in vivo, although there was no
significant difference in total cell numbers among siRTP801-
treated wells (568.1 6 24.1 cells/well), sNBA controls (518.6
6 42.6), and siEGFP controls (537 6 26.1) (Figs. 8A, 8B) 3
days after siRNA transfection. The expression of RTP801 in
activated GFAPþ glia was significantly reduced (P < 0.001) by
siRTP801 treatment (40.2% 6 5.4%) compared with sNBA
(81.2% 6 3.9%) and siEGFP-treated controls (84.4% 6 4.3%)
(Fig. 8C). These data showed that RTP801 was expressed in
activated astrocytes and Mu¨ller glia, and that siRTP801 induced
target knockdown in these cells without affecting the total
number of GFAPþ activated glia.
The siRTP801 Was RGC Neuroprotective and Promot-
ed Neurite Elongation in the Presence of Activated
Retinal Glia. In the presence of activated retinal glia in
vitro, the number of surviving bIII-tubulinþ RGCs significantly
increased (P < 0.001) from 299.5 6 27.9 and 264.7 6 28.9 in
sNBA and siEGFP control wells, respectively, to 605.3 6 31.3
cells after siRTP801 treatment (Figs. 9A, 9B). These data are
comparable to cultures established from intact eyes (Fig. 6),
indicating both that significant RGC death had not yet
occurred in vivo 5 days after ONC, and also that the presence
of activated retinal glia in culture did not affect the pro-
survival effect of siRTP801. There was no statistically
significant difference in the proportion of neurite-bearing
RGCs between siRTP801-treated wells (37.2% 6 4.9%) and
sNBA- (26.8% 6 5.2%) or siEGFP-treated (24.8% 6 5.5%)
controls (Fig. 9C), comparable to observations in the absence
of activated retinal glia. However, whereas the mean length of
the longest neurite extending from RGCs was 36 6 8 lm and
34 6 6 lm for sNBA and siEGFP controls, respectively, it was
significantly longer (78 6 12 lm; P < 0.05) after siRTP801
treatment (Figs. 9A, 9D). Thus, similar to in vivo data,
siRTP801 promoted both RGC survival and neurite elonga-
tion, but not neurite initiation, in the presence of activated
retinal glia.
The contribution of mTORC1 signaling to siRTP801-
induced RGC neuroprotection and neurite elongation in the
presence of activated glia was examined in retinal cultures in
the presence of rapamycin, which completely abolished
cellular expression of pS6 (Supplementary Fig. S3). The
RGC neuroprotective effect of siRTP801 in culture was
significantly reduced (P < 0.05) in the presence of rapamycin
(452.0 6 36.1), but not abolished, indicating both mTORC1-
dependent and mTORC1-independent mechanisms contrib-
FIGURE 6. Knockdown of RTP801, RGC survival, and neurite growth
in cultured retinal cells in the absence of activated retinal glia. (A)
Proportion of bIII-tubulinþ RGC expressing RTP801 after treatment
with 20 nM siRTP801 compared with controls (**P < 0.01 versus sNBA
control). (B) Quantification of RTP801þ bIII-tubulin nonneuronal cells
(***P < 0.001 versus sNBA control). (C) Retinal cultures immuno-
stained for bIII-tubulin (green) and RTP801 (red) after 3 days in culture.
Scale bar: 20 lm. (D) Quantification of surviving bIII-tubulinþ RGC
after 3 days in culture (***P < 0.001 versus sNBA control). (E)
Proportion of surviving bIII-tubulinþ RGC extending neurites. (F)
Length of longest neurites in bIII-tubulinþ RGC.
FIGURE 7. Expression of glial antibody markers in nonactivated retinal
cultures and RTP801 knockdown in retinal glia. Retinal cultures
established from uninjured animals immunostained for (A) GFAP
(green) and RTP801 (red), and (B) S100b (green) and RTP801 (red)
after 3 days in culture with sNBA culture medium, siEGFP, and
siRTP801, indicating RTP801 expression in glia, and knockdown in
siRTP801-treated wells; DAPI (blue) was used as a nuclear counter-
stain. Scale bar: 20 lm. (C) Quantification of S100bþ cells in retinal
cultures described in (A), indicating no significant glial proliferation or
toxicity between treatment groups. (D) Proportion of S100bþ glia
expressing RTP801 after siRTP801 treatment compared with controls
(*P < 0.05, **P < 0.01).
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uting to the siRTP801-mediated RGC survival effect (Figs. 9A,
9B). Rapamycin did not reduce the number of bIII-tubulinþ
RGCs in control wells, suggesting that rapamycin was not
RGC neurotoxic in this model (Figs. 9A, 9B). Rapamycin also
had no significant effect on RGC neuritogenesis (Figs. 9A, 9C),
but did reduce mean neurite length in siRTP801-treated wells
(54 6 6 lm) (Figs. 9A, 9D), although the latter result did not
reach statistical significance (Fig. 9D), suggesting that
siRTP801-induced neurite elongation was partially mTORC1
independent.
Glial Activation and the Production of Neurotrophins
Were Both Potentiated by siRTP801. In medium from
retinal cell cultures in which activated retinal glia were absent,
titers of NGF, NT-3, and BDNF were very low or undetectable
(Fig. 10, blue bars). After glial activation by previous ONC,
titers of BDNF, NGF, and NT-3 were increased (Fig. 10, red
bars), and significantly higher levels of NGF (P < 0.001), NT-3
(P < 0.01), and BDNF (P < 0.001) were present after siRTP801
treatment when compared with sNBA and siEGFP treatments
(Fig. 10, red bars). These data suggested that activation of
retinal glia by ONC led to the production and release of NTF, an
effect that was potentiated by siRTP801 treatment but not
initiated by it.
The siRTP801 Protected Against Injury-Induced pS6
Downregulation, Although siRTP801-Induced Neurite
Outgrowth Did Not Require S6 Phosphorylation. In
retinal cultures prepared from uninjured animals, 23.1% 6
1.7% RGCs were pS6þ (Figs. 11A, 11B). After ONC, the
proportion of RGCs in culture expressing pS6 was reduced to
9.2% 6 3.1% and 6.7% 6 2.7% in sNBA and siEGFP-treated
controls, respectively (Figs. 11A, 11B). In cultures treated
with siRTP801 after ONC, pS6 expression was maintained at a
level not significantly different from uninjured control
cultures (23.5% 6 3.9%) (Figs. 11A, 11B), suggesting that
siRTP801 treatment prevented injury-induced pS6 downreg-
ulation in RGCs, which reflects maintained mTORC1 activity.
Detection of pS6 was not limited to RGCs, as bIII-tubulin
cells also expressed pS6, suggesting mTORC1 activity also in
glia (Fig. 11A). Detection of pS6 was observed in 51.1% 6
9.8% and 41% 6 5.8% neurite-bearing RGCs in sNBA- and
siEGFP-treated control wells, and this proportion was not
significantly increased after siRTP801 treatment (52.1% 6
4.8%) (Figs. 12A, 12B). Furthermore, neurite outgrowth was
not limited to pS6þ RGC, as many pS6/bIII-tubulinþ RGC
extended neurites (Fig. 12A). In keeping with the in vivo
findings, these data demonstrated that siRTP801 maintained
mTORC1 activity in retinal cells after injury and neurite
outgrowth was more likely in pS6þ RGC, although the
expression of this marker was not obligatory for RGC neurite
outgrowth after glia activation.
FIGURE 8. The GFAPþ activated glia and RTP801 knockdown in
activated glia in retinal cultures established 5 days after ONC. (A)
Immunostaining of cultured retinal cells by GFAP (green) and RTP801
(red) after treatment with siRTP801 and controls; DAPI (blue) was
used as a nuclear counterstain. Scale bar: 20 lm. (B) Quantification of
GFAPþ cells in glial-activated retinal cultures after 3 days in culture.
(C) Proportion of GFAPþ glia expressing RTP801 after siRTP801
treatment compared with controls after 3 days in culture (***P <
0.001).
FIGURE 9. Retinal ganglion cell survival and neurite growth in the
presence of activated glia in vitro, and effects of mTORC1 inhibition
with rapamycin. (A) bIII-tubulinþ RGC (green) after siRTP801
treatment and in controls in the presence of activated retinal glia, in
the absence of inhibitor (left column) and in the presence of 10 nM
rapamycin (right column); DAPI (blue) was used as a nuclear
counterstain. Scale bar: 20 lm. The numbers of surviving bIII-tubulinþ
RGC (B), the proportion of bIII-tubulinþ RGC extending neurites (C),
and the length of longest RGC neurites (D) after 3 days in culture in the
absence of inhibitor (blue bars), and in the presence of rapamycin (red
bars) (*P < 0.05, ***P < 0.001).
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DISCUSSION
Recent studies have implied a key role for mTOR signaling in
RGC survival and axon regeneration and have suggested that
this pathway is a potentially useful therapeutic target for
neurodegenerative conditions. However, the most impressive
results have been achieved with laboratory techniques that are
largely not clinically translatable,31,64,65 and mechanisms
underpinning the neuroprotective/regenerative effects report-
ed are not well defined. Accordingly, this study investigated the
effects of a clinically translatable siRNA targeting RTP801, a
stress-induced negative regulator of mTOR signaling, on RGC
survival, axon regeneration, and activation of retinal glia after
ONC in vivo, and used retinal cultures to investigate potential
underlying mechanisms. Expression of RTP801 is not limited to
RGCs, and we have observed both expression and siRNA-
mediated knockdown in RGC and glia, consistent with
previous findings that RTP801 is expressed in several retinal
layers, and is susceptible to siRNA-mediated knockdown
within 1 day after intravitreal injection.44,47
The major findings in vivo were that, compared with siEGFP
controls, siRTP801 intravitreal treatment after ONC promoted
significant RGC neuroprotection and, although the numbers of
RGC axons sprouting at the lesion site and into the distal ON
segment adjacent to the lesion were not increased, more axons
extended 400 to 1200 lm beyond the ONC. Hence, siRTP801
treatment promoted axon elongation but did not stimulate
axogenesis. Suppression of RTP801 activity also prevented
injury-induced downregulation of mTORC1 activity and
potentiated ONC-induced retinal astrocyte/Mu¨ller glial activa-
tion. This glial activation was probably specific in view of the
lack of nonspecific proinflammatory activity of this siRNA,
which, if it exists, is mediated via TLR activation known as a
promoter of glia activation.66
Although the anatomical integrity of retinal tissues is not
maintained in culture, our experiments indicate that use of in
vitro studies can be informative with regard to identifying
underlying cellular mechanisms. As in uninjured control
animals in vivo, retinal cultures obtained from uninjured adult
rats demonstrated an absence of GFAPþ activated glia, but
treatment with siRTP801 promoted RGC neuroprotection in
these cultures, indicating a direct effect on RGC-intrinsic
mTOR signaling for cell survival. Neurite outgrowth was not
affected by siRTP801 in the absence of activated retinal glia;
however, consistent with previous reports, retinal cultures
prepared 5 days after ONC contained GFAPþ activated
glia,19,23,25,67 and therefore may be considered more represen-
tative of the postinjury in vivo condition. The siRTP801 had no
significant effect on initiation of neurite outgrowth, but
promoted longer neurite growth, suggesting that additional
factors were present in glial-activated cultures that enabled
more sustained neurite outgrowth. Such factors could be
neurotrophins secreted by activated glia and which production
appeared potentiated by siRTP801 treatment. These in vitro
data closely correlate with our in vivo findings that siRTP801
did not significantly affect the number of RGC axons sprouting
at the lesion site, but did promote growth of longer axons
regenerating into the distal ON segment, associated with
maintenance of mTORC1 activity. Although the culture of
retinal cells after ONC and subsequent in vitro siRNA treatment
and analysis may be associated with potential mechanistic
differences from the in vivo conditions, this approach closely
FIGURE 10. Neurotrophic factor titers in conditioned culture medium
from retinal cultures in the absence or presence of activated retinal
glia. Titers of BDNF (A), NGF (B), and NT-3 (C) in culture medium
measured by ELISA in the absence (blue bars) or presence (red bars)
of activated retinal glia, after treatment with siRTP801 or controls (*P <
0.05, **P < 0.01, ***P < 0.001).
FIGURE 11. Activity of mTORC1 (pS6 expression) in cultured retinal
cells. (A) Retinal cells immunostained for bIII-tubulin (green) and pS6
(red) in cultures obtained from uninjured control animals, and 5 days
after ONC and then treated with siRTP801 or sNBA/siEGFP controls.
Note the detection of pS6 both in bIII-tubulinþ RGC (arrows) and glia
(arrowheads); DAPI (blue) was used as a nuclear counterstain. Scale
bar: 20 lm. (B) The proportion of bIII-tubulinþ RGC expressing pS6
after 3 days in culture for conditions described in (A) (*P < 0.05, **P <
0.01).
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models the glial activation seen in vivo, and enables multiple
analyses of biological processes while minimizing animal
usage. Moreover, the concordance between the observations
in the glial-activated culture paradigm and the in vivo setting
support this strategy in evaluating underlying cellular mecha-
nisms. Thus, our data suggest that the observed RGC survival
and axon/neurite elongation after siRTP801 treatment reflect
both direct effects on RGC and indirect sequelae attributable to
RTP801 suppression in astrocytes and Mu¨ller glia.
The observed neuroprotective effect of siRTP801 in the
ONC model is consistent with previous reports on the effects
of RTP801 overexpression or knockdown/knockout in the
nervous system. Overexpression of RTP801 in nondividing
neuron-like PC12 cells promotes apoptosis,43 and RTP801
knockout mice exhibit reduced neuronal apoptosis in a murine
model of retinopathy of prematurity.45 Expression of RTP801 is
elevated in substantia nigra neurons and associated with cell
death both in a murine Parkinson’s disease (PD) model and in
human PD postmortem brains, and knockdown of RTP801
protects cultured neurons from apoptosis in cellular PD
models.68 Furthermore, siRNA-mediated knockdown of
RTP801 protects RGC-5 neurons from blue light– and cobalt
chloride–induced cell death.44 Thus, RTP801 inhibition is a
viable neuroprotective strategy supported by diverse and solid
experimental data.
RTP801 is rapidly upregulated in response to cellular stress/
injury and acts on the TSC1/2 complex to suppress mTOR
signaling.37,40 After axotomy, a reduction in the supply of
available target/glial-derived NTF, which normally promote
mTOR activity via receptor-activated PI3K/Akt signaling, is
compounded by RTP801 upregulation, which acts to further
suppress mTOR. Our approach of inhibiting RTP801 to
promote mTOR activity compares favorably with other
strategies aimed at increasing PI3K pathway signaling for
RGC survival. For example, RGC survival of 45% is observed
after conditional deletion of PTEN at 14 days after ONC in
mice,31 but rises to 60% when PI3K-pathway upregulation is
combined with adjunctive SOCS3 deletion and CNTF admin-
istration.64 We observed RGC survival of approximately 45%
with our control siRNA at 24 days after ONC, which could be
associated with induction of an inflammatory response69 that
may promote neuroprotection after RGC axotomy.22 However,
we have not observed significant differences in RGC survival
between siEGFP and PBS in this model (Supplementary Table
S1), and siEGFP transfection of retinal cultures from intact
animals not associated with the presence of GFAPþ activated
retinal glia, indicating a lack of immunogenicity of the control
siRNA. Furthermore, in all the in vitro analyses undertaken,
there were no significant differences between control siEGFP
and the sNBA culture medium alone, therefore demonstrating
the inactivity of control siRNA in these studies and enabling the
phenotypic effects of siRTP801 to be attributed to the
sequence specificity of this siRNA, rather than due to an
siRNA class effect. Intravitreal delivery of siRTP801 promoted
favorable RGC neuroprotection, although recent reports
suggest that RGC survival after ONC may be subtype specific,
with M1-RGC and aRGC preferentially surviving after ONC.70 It
remains to be investigated whether siRTP801-induced RGC
neuroprotection differentially affects RGC classes after ONC,
but our results indicate that RTP801 inhibition may be a useful
component of future treatment strategies to prevent visual loss
after ON injury.
Our findings suggested that RTP801 knockdown support-
ed the elongation of regenerating axons rather than the
initiation of axogenesis after ONC. There was, however, a
marked disparity between the potent RGC neuroprotective
effect of siRTP801 and the relatively limited axon regenera-
tion, confirming that axon regeneration is not inevitable in
surviving RGCs.19,71 A typical rodent ON contains approxi-
mately 100,000 RGC axons,72 and thus the number of
regenerating axons we observed represents a regenerative
response in fewer than 0.1% RGCs. Nonetheless, our results
complement the increasing literature implicating the PI3K/
Akt/mTOR pathway as a mediator of axon regeneration in
several models of CNS injury.29,31,34,35 Robust ON axon
regeneration is reported after PTEN deletion, associated with
the maintenance of RGC pS6 expression,31 whereas RTP801
modulates the PI3K signaling pathway further downstream
the pathway, acting on the TSC1/2 complex.37,40 A more
muted regenerative response is observed after deletion of TSC
compared with PTEN,31 possibly reflecting differential
signaling through the GSK3b pathway.29,31 Moreover, axon
regeneration after PTEN deletion is restricted to predomi-
nantly the aRGC subtype, which is preferentially resistant to
apoptosis after ONC,70 and so the predominant weighting of
RTP801 knockdown in favor of survival compared with axon/
neurite growth may reflect survival of RGC subtypes in which
a regenerative response is not possible, with mTOR-related
protein synthesis maintaining neuronal viability and contrib-
uting to growth of axons that have initiated regeneration in
response to other triggers. In agreement with our data, mTOR
activity has been implicated as an important factor in the
maintenance of an axon growth state,73 whereas initiation of
the axogenic program may be dependent on separate,
although complementary, pathways such as CNTF/LIF-medi-
ated JAK-STAT activity.21–23,26,73,74
Previous studies investigating the role of PI3K-mTOR
signaling on neuronal survival and axon regeneration have
focused on RGC responses alone, rather than on the
contribution of glial-derived factors. Retinal glial activation/
reactive gliosis has a major influence on RGC axon
regeneration through the production and release of neuro-
trophins and other proregenerative and inflammatory cyto-
kines, which modulate the injury response through autocrine
and paracrine mechanisms.19,23–26,75–78 Development of RGC
neuroprotective/regenerative therapies must therefore ac-
knowledge the glial response and associated cellular signal-
ing.
FIGURE 12. Expression of pS6 in both neurite-bearing and non–
neurite-bearing RGCs. (A) Retinal cultures immunostained for bIII-
tubulin (green) and pS6 (red): pS6þ RGC with neurite (closed arrow),
pS6 RGC with neurite (dashed open arrow), pS6þ RGC without
neurite (closed arrowhead), pS6 RGC without neurite (open
arrowhead); DAPI (blue) was used as a nuclear counterstain. Scale
bar: 20 lm. (B) The proportion of neurite-bearing RGCs expressing
pS6 in controls and after siRTP801 treatment (no significant difference
between groups).
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Our observation of specific (in the absence of induction of
nonspecific innate TLR-mediated responses) potentiated
retinal astrocyte/Mu¨ller glial activation by siRTP801 is
consistent with a role for activated glia in mediating
neuroprotection and axon elongation. This in vivo observa-
tion was supported by in vitro data in mixed retinal cultures
treated with siRTP801. Although being unable to induce glia
activation directly in cultures derived from intact eyes,
siRTP801 treatment of cultures comprising already activated
glia (established 5 days after ONC) resulted in potentiation of
the secretory phenotype of the activated glia (i.e., in
significantly increased production of neurotrophins BDNF,
NGF, and NT-3). Interestingly, the presence of activated glia in
retinal cultures was an absolute requirement for the axon
elongation effect of siRTP801, suggesting that despite
activated glia promoting NTF production, axon growth may
be limited by the downstream inactivation of mTOR by
RTP801 in control wells. Inhibition of RTP801 therefore
appears both to potentiate glia NTF production, and to
disinhibit the RGC response to enable longer neurite growth.
Potentiation of reactive gliosis may not be beneficial in all
optic neuropathies, as aspects of the retinal glial response
may be detrimental to RGC viability and axon growth in some
circumstances. In glaucoma, for example, activated microg-
lial-derived proinflammatory factors, such as TNF-a and IL-6,
may induce neurotoxicity rather than neuroprotection.79
Time-course analyses of gene expression changes during
reactive gliosis found more than 1300 genes differentially
expressed within 1 day of ONC, with functionally distinct
groups of temporally specific genes associated with inflam-
matory responses, tissue remodeling, and structural alter-
ations.80 Modulation of retinal gliosis to optimize RGC
survival and axon regeneration must therefore consider
multiple tissue-specific, injury-specific, and temporal factors.
There was approximately equivalent RGC survival both in
the absence and presence of activated retinal glia in vitro,
indicating that siRTP801-mediated neuroprotection predomi-
nantly stemmed from a direct effect on RGCs. This effect was
only partially mTORC1-dependent, as rapamycin treatment
abolished pS6 expression (a correlate of mTORC1 activity), yet
only partially attenuated siRTP801 neuroprotection. Both
initiation of neurite sprouting and elongation of neurite growth
were predominantly independent of mTORC1 activity, consis-
tent in part with previous observations that rapamycin reduced
but did not abolish axon regeneration after PTEN knockout.31
Moreover, accelerated neurite outgrowth in the peripheral
nervous system after PTEN inhibition is unaltered by rapamy-
cin.34 Our data are also consistent with the results of Leibinger
et al.,73 who found that, although inflammation-induced RGC
neurite outgrowth is rapamycin insensitive, it does require
mTORC1 activity for the maintenance of a regenerative state. It
is likely, therefore, that initiation of axon/neurite growth is
mTORC1 independent, but under the right cellular conditions
mTORC1 has a key role in maintaining axonal growth.
Treatment with siRTP801 prevented injury-induced down-
regulation of mTORC1 activity, both after ONC in vivo and in
the culture model. Rapamycin-sensitive mTORC1 activity
seemed to contribute to, but was not obligatory for,
neuroprotection and axon/neurite growth elicited by
siRTP801, thus implicating alternative intracellular signaling
pathways; among them, the relatively rapamycin-insensitive
mTORC2 is a primary candidate.30 The mTORC2 is also
downstream to RTP801/TSC1/2 and is likely to contribute to
neuroprotection/axon growth by siRTP801 in the presence of
rapamycin. The mTORC2 influences cellular processes either
through the downstream substrate PKCa, which is associated
with actin dynamics and may influence growth cone activity,30
or by feedback phosphorylation and activation of Akt, which in
turn regulates the activity of other growth and cell survival
mediators, such as GSK3b,29,81 and components of mitochon-
drial apoptosis machinery.82 Several reports provide evidence
that GSK3b inhibition is associated with enhanced neuronal
growth.83–85
In summary, siRTP801-dependent potentiation of PI3K
pathway signaling in RGCs via paracrine secretion of
neurotrophins by activated glia combined with siRTP801-
mediated activation of both mTORC1 and mTORC2 in RGCs
themselves may be responsible for the observed increased
survival and longer axon/neurite growth seen after siRTP801
treatment both in vitro (mixed retinal cultures) and in vivo.
The challenge remains for the development of novel
neuroprotective and axon regenerative therapies that can be
used for the benefit of patients.78 Clinical trials of intravitreal
siRNA treatments, including those targeting RTP801, have
reported safety and efficacy for ocular diseases.48,50,86 Despite
the inherent vulnerabilities of immunofluorescence-based
analyses, such as antibody specificity and limitations of
sampling for neuronal/glial quantification, both our in vivo
and in vitro observations yielded consistent results. Here, we
show that siRNA-mediated knockdown of RTP801 promotes
RGC neuroprotection, supports elongation of regenerating
axons after ONC in vivo, and potentiates a proregenerative
reactive glial response to injury. Furthermore, RGC neuro-
protection is predominantly directly mediated, via mTORC1-
dependent and independent components, whereas siRTP801-
induced neurite elongation uses an indirect mechanism,
requiring the presence of activated retinal glial-derived NTF
and is independent of mTORC1 activity. Understanding the
mechanisms underpinning the neuronal responses achieved
with siRNA treatments is critical to improving their efficacy
and pointing the way to exploring more defined combinato-
rial approaches. Importantly, this siRNA-based approach is
potentially rapidly translational, and may contribute to future
strategies to promote RGC survival and axon regeneration
after ocular and ON injuries.
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